Please assess the completion status of the following clinical trial:

Trial Title: This Was a Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistamines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects aged ≥18 years of age~* CSU diagnosis for ≥ 6 months prior to screening~* Presence of itch and hives for ≥6 consecutive weeks prior to screening in spite of use of non-sedating H1-antihistamines according to local Treatment guidelines during this time period~* UAS7 score (range 0-42) ≥16 and HSS7 score (range 0-21) ≥ 8 during 7 days prior to randomization (Day 1)~* Willing and able to complete an Urticaria Participant Daily eDiary (UPDD) for the duration of the study~Exclusion Criteria:~* Hypersensitivity to any of the study treatments~* Clearly defined predominant or sole trigger of their chronic urticaria (chronic inducible urticaria)~* Other diseases with symptoms of urticaria or angioedema~* Other skin disease associated with chronic itching that might influence in the investigators opinion the study evaluations and results,~* Known or suspected history of an ongoing, chronic or recurrent infectious disease including but not limited to opportunistic infections (eg tuberculosis, atypical mycobacterioses, listeriosis or aspergillosis), HIV, Hepatitis B/C.~* Pregnant or nursing (lactating) women~* Women of child-bearing potential not using highly effective methods of contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- LOU064 Arm 1 (Type: EXPERIMENTAL): 10 mg LOU064 qd capsule once daily
- LOU064 Arm 2 (Type: EXPERIMENTAL): 35 mg capsule qd LOU064 once daily
- LOU064 Arm 3 (Type: EXPERIMENTAL): 100 mg capsule qd LOU064 once daily
- LOU064 Arm 4 (Type: EXPERIMENTAL): 10 mg capsule LOU064 bid
- LOU064 Arm 5 (Type: EXPERIMENTAL): 25 mg capsule LOU064 bid
- LOU064 Arm 6 (Type: EXPERIMENTAL): 100 mg capsule LOU064 bid
- Placebo Arm (Type: PLACEBO_COMPARATOR): Participants took matching placebo twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).